In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Fogarty Institute For Innovation: A Device Incubator For Difficult Times

Executive Summary

Go to any gathering of medical device start-up CEOs and their investors, and beneath a veneer of passionate intensity about individual technology lie concern, anxiety, and in some cases, real pessimism. Central to the debate: is the device innovation model broken? Six years ago, one of the most celebrated device entrepreneurs, Tom Fogarty, MD, working with officials at El Camino Hospital in Mountain View, CA, an independent community hospital located in the heart of the San Francisco device community, launched the Fogarty Institute for Innovation, an initiative designed to help the earliest-stage companies ramp up technology development quickly and efficiently in an effort to minimize, if not eliminate the external challenges. To date, the Institute has started or nurtured five companies.

You may also be interested in...



Protecting Device Innovation: An Interview With Tom Fogarty

Noted physician-entrepreneur Tom Fogarty has long been known for inventing breakthrough products. Here he discusses his recent efforts to protect the medical device innovation model, and corrects what he sees as serious flaws in its long-term viability, especially in the U.S.

Protecting Device Innovation: An Interview With Tom Fogarty

Noted physician/entrepreneur Tom Fogarty has long been known for inventing breakthrough new products, but here he discusses his recent efforts focused on working to protect the medical device innovation model and correct what he sees as serious flaws that may hinder its long-term viability, especially in the US.

Medtech Investing: A Survivor’s Game

At Elsevier Business Intelligence's IN3 conference in October 2012, a panel of venture capital investors talked about the current difficult financing climate for medtech start-ups, although a ray of hope lights the future.

Related Content

Related Companies

UsernamePublicRestriction

Register

IV003677

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel